Celgene is buying cancer drugmaker Juno Therapeutics for $9 billion – Markets Insider
Endpoints News |
Celgene is buying cancer drugmaker Juno Therapeutics for $9 billion
Markets Insider One challenge these therapies still face is how toxic they can be. CAR–T's side effects can be deadly. In May 2017, Kite disclosed that one person had died in a clinical trial for its late-stage CAR–T therapy from cerebral edema, a condition in which … Celgene to buy Juno for $9 billion to boost CAR–T expertise UPDATED: Celgene bags CAR–T player Juno in $9B buyout as biotech M&A suddenly explodes Shares of biotech Juno, already up 50% on deal hopes, skyrocket on actual Celgene $9 billion offer |
